p21(Waf1/Cip1) and p53 protein expression in breast cancer

American Journal of Clinical Pathology
E WakasugiM Monden

Abstract

p21/Cip1/Waf1 (wild-type p53 activated fragment 1/cyclin-dependent kinase [Cdk]-interacting protein 1) is a prominent Cdk inhibitor and has been shown to be a downstream mediator of p53. In this study, we sought to clarify the clinical significance of Waf1 and the relationship between Waf1 and p53 in breast cancer. For this purpose, the expressions of Waf1 and p53 were evaluated immunohistochemically in a series of 104 patients. Waf1 was expressed in 51 (49%) of 104 tumors tested, and p53 in 33 tumors (32%). Inverse expression of these two proteins was seen in 76 cases (73%); 47 were Waf1-positive and p53-negative, and 29 were Waf1-negative and p53-positive. A comparison with clinicopathologic parameters showed that Waf1 expression correlated with negative lymph nodes (P<.01), a low histologic grade (P<.0001), and positive estrogen receptor status (P<.01). Recurrence-free survival was lower for patients with Waf1-negative tumors than for those with Waf1-positive tumors (P<.0001). In multivariate analysis, Waf1 expression and low histologic grade (1 or 2) tumors had an independent prognostic significance for recurrence-free survival. These results suggest that Waf1 is induced mainly by a p53-dependent pathway and could be a reli...Continue Reading

Citations

Mar 12, 1999·Annual Review of Medicine·J TsihliasJ Slingerland
Mar 10, 2001·International Journal of Cancer. Journal International Du Cancer·C CeccarelliD Marrano
Mar 4, 2005·Molecular and Cellular Biology·Asmaà FritahMichèle Sabbah
Sep 24, 2015·DNA and Cell Biology·Mahboobeh AshrafiMahshid Azizian
Jun 2, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Yong-Sheng HuangLin Wang
Nov 1, 1998·Journal of Gastroenterology and Hepatology·Irene Ol Ng
Sep 27, 2018·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Samir F ZohnyHani Choudhry
Feb 5, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·T MoriyaJ Ito
Jul 22, 1998·Journal of the National Cancer Institute·R E Millikan, C J Logothetis
Jul 26, 2000·Proceedings of the National Academy of Sciences of the United States of America·S CariouJ M Slingerland
Jan 22, 2008·International Journal of Surgical Pathology·Tatsuki R KataokaYasuko Nishizawa
Apr 27, 2007·Breast Cancer Research and Treatment·Natasha B LeighlMalcolm J Moore
Aug 12, 1998·International Journal of Cancer. Journal International Du Cancer·L F QinM Ng
Jul 1, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y ItoM Monden
Dec 6, 2005·Journal of Cancer Research and Clinical Oncology·Annette Schmider-RossAngela Reles
Aug 10, 2000·Breast Cancer Research and Treatment·A D ThorS M Edgerton
Mar 19, 2002·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Mark Yen-Ping KuoChun-Pin Chiang
Sep 12, 2012·Molecular Cancer Research : MCR·Marie MaynadierMarcel Garcia
Jan 9, 2021·British Journal of Cancer·Sunil S BadveFiona Ginty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.